Trial record 1 of 1 for:
IDE196-009
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05907954 |
|
Recruitment Status :
Recruiting
First Posted : June 18, 2023
Last Update Posted : March 28, 2024
|
Sponsor:
IDEAYA Biosciences
Information provided by (Responsible Party):
IDEAYA Biosciences
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Uveal Melanoma | Drug: Darovasertib | Phase 2 |
Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to assess visual outcome, disease recurrence, and development of metastatic disease.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 82 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma |
| Actual Study Start Date : | July 3, 2023 |
| Estimated Primary Completion Date : | January 31, 2026 |
| Estimated Study Completion Date : | January 31, 2029 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Melanoma
MedlinePlus related topics:
Melanoma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: darovasertib
IDE196 (darovasertib) oral open label
|
Drug: Darovasertib
Oral, potent, selective inhibitor of Protein Kinase C
Other Names:
|
Primary Outcome Measures :
- Incidence of Adverse Events (AEs) and significant laboratory abnormalities [ Time Frame: from first dose to last dose of adjuvant therapy, approximately 12 months ]Treatment emergent adverse events will be summarized by all AEs, all Grade 3-4-5 AEs, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs. Lab results will be summarized by change from baseline values, frequency of newly occurring on-treatment Grade 3 or 4 events; worst on-treatment value compared to baseline.
- Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation [ Time Frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 6 months ]Rate of eye salvage as determined by the ocular oncologist based on tumor response to neoadjuvant therapy
- Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose [ Time Frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 6 months ]Change in modeled radiation dose at critical eye structures before and after neoadjuvant therapy
Secondary Outcome Measures :
- Evaluate tumor response to neoadjuvant IDE196 [ Time Frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 6 months ]Measurement of tumor diameter and thickness before and after neoadjuvant therapy with IDE196, specifically as measured by ocular ultrasound, evaluating largest basal diameter and apical thickness of the uveal melanoma (measured in millimeters)
- Assessment of visual acuity loss [ Time Frame: from time of primary local therapy to one year after surgery, approximately 12 months ]Best corrected visual acuity loss over time
- Rate of local disease recurrence [ Time Frame: from date of primary local therapy to end of follow-up, approximately 36 months ]Evaluate uveal melanoma progression or recurrence
- Rate of metastatic disease [ Time Frame: from date of primary local therapy to end of follow-up, approximately 36 months ]Evaluate occurrence of metastatic uveal melanoma
Other Outcome Measures:
- Overall survival [ Time Frame: from date of first dose to end of follow-up, approximately 44 months ]Evaluate patient survival status
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
- Able to dose orally
- ECOG Performance status of 0-1
- No other significant underlying ocular disease
- Adequate organ function
- Not pregnant/nursing or planning to become pregnant. Willing to use birth control
Exclusion Criteria:
- Previous treatment with a Protein Kinase C (PKC) inhibitor
- Concurrent malignant disease
- Active HIV infection or Hep B/C
- Malabsorption disorder
- Unable to discontinue prohibited medication
- Impaired cardiac function or clinically significant cardiac disease
- Any other condition which may interfere with study interpretation or results
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05907954
Contacts
| Contact: IDEAYA Clinical Trials | 1 650-534-3616 | IDEAYAClinicalTrials@ideayabio.com | |
| Contact: Jasgit Sachdev, MD | jsachdev@ideayabio.com |
Locations
Show 22 study locations
Sponsors and Collaborators
IDEAYA Biosciences
Investigators
| Study Director: | Jasgit Sachdev, MD | IDEAYA Biosciences |
| Responsible Party: | IDEAYA Biosciences |
| ClinicalTrials.gov Identifier: | NCT05907954 |
| Other Study ID Numbers: |
IDE196-009 |
| First Posted: | June 18, 2023 Key Record Dates |
| Last Update Posted: | March 28, 2024 |
| Last Verified: | November 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by IDEAYA Biosciences:
|
Uveal Melanoma Plaque brachytherapy Enucleation Neoadjuvant Adjuvant Protein Kinase C Ophthalmology |
Ocular Oncology Darovasertib IDE196 Ocular melanoma Choroid melanoma Plaque Brachytherapy |
Additional relevant MeSH terms:
|
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms by Site Skin Diseases |